Latanoprost as a new horizon in the medical management of glaucoma

Current Opinion in Ophthalmology

Volumn 7, Issue 2, 1996, Pages 11-17

  Stjernschantz, Johan ^a   Alm, Albert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; PILOCARPINE; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; TIMOLOL;

AQUEOUS HUMOR OUTFLOW; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EYE COLOR; EYE IRRITATION; GLAUCOMA; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; KERATOPATHY; MELANOGENESIS; NONHUMAN; PIGMENT DISORDER; PRIORITY JOURNAL; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0029781496     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199604000-00003     Document Type: Review

References (44)

1. 2α. Curr Eye Res 1981, 1:205-209.
2. Bito LZ, Camras CB, Glenwood GG, Resul R: The Ocular Hypotensive Effects and Side Eects of Prostaglandins on the Eye of Experimental Animals. In The Ocular Effects of Prostaglandins and Other Eicosanoids. Edited by Bito LZ, Stjernschantz J. New York: Alan R. Liss; 1989:349-368.
3. 2α and its Isopropylester on Normal and Glaucomatous Human Eyes. In The Ocular Effects of Prostaglandins and Other Eicosanoids. Edited by Bito LZ, Stjernschantz J. New York: Alan R. Liss; 1989:447-458.
4. Alm A: The potential of prostaglandin derivates in glaucoma therapy. Curr Opin Ophthalmol 1993, 4:44-50.
5. 2α. Arch Ophthalmol 1987, 105:1112-1116.
6. 2α-1- isopropyl ester in the cynomologus monkey. Exp Eye Res 1989, 48:707-716.
7. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989, 49:389-402.
8. 2α Analogue, vol 23. In Advances in Prostaglandin, Tromboxane, and Leukotriene Research. Edited by Samuelsson B. New York: Raven Press; 1995:513-518.
9. Coleman RA, Smith WL, Narumiya S: International union of pharmacol•• ogy classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994, 46:205-229. This review article gives comprehensive and detailed information about the classification of prostanoid receptors based on both molecular biological and pharmacologic data. Subtypes and isoforms of prostanoid receptors and their second messenger systems are described as well as agonists and antagonists for the different receptors.
10. Sugimoto Y. Negishi M, Hayashi Y, Namba T, Honda A, Watabe A, Hirata M, Narumiya S, Ichikawa A: Two isoforms of the EP3 receptor with different carboxyl-terminal domains. J Biol Chem 1993, 268:2712-2718.
11. 3 prostanoid receptor. Febs Lett 1994, 338:170-174.
12. Pierce KL, Gil DW, Woodward DF, Regan JW: Cloning of human prostanoid receptors. Trends Pharmacol Sci 1995, 16:253-256.
13. 2α receptor in the monkey eye. Invest Ophthalmol Vis Sci 1995, 36:A2765.
14. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology 1993, 100:1297-1304.
15. Astin M, Gjötterberg M, Holst A, Selën G, Resul B, Stjernschantz J: Study of the fundus in phakic and aphakic monkey eyes treated with PhXA41. Invest Ophthalmol Vis Sci 1992, 33:1078.
16. Green K, Paterson CA, Siddiqui A: Ocular blood flow after experimental alkali burns and prostaglandin administration. Arch Ophthalmol 1985, 103:569-571.
17. Stjernschantz J, Nilsson SPE, Astin M: Vasodynamic and Angiogenic Effects of Eicosanoids in the Eye. In The Ocular Effects of Prostaglandins and Other Eicosanoids. Edited by Bito LZ, Stjernschantz J. New York: Alan R. Liss; 1989:155-170.
18. 2α-induced ocular hyperemia. Exp Eye Res 1994, 59:401-408.
19. Ziai N, Dolan WJ, Kacere RD, Brubaker RF: The effects on aqueous dynamics of RhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes Arch Ophthalmol 1993, 111:1351-1358.
20. 2α- isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol 1993, 37:259-269.
21. Selën G, Stjernschantz J, Resul B, Bito LZ: Prostaglandin-induced in• crease in iris pigmentation. Surv Ophthalmol 1996, in press. This article describes the melanogenic effect of naturally occurring and synthetic prostaglandins in the primate iris.
22. Hu F, Mah K: Changes in melanosomes with age in iridial stromal melanocytes of rhesus macaques. Mech Ageing Dev 1983, 23:95-102.
23. Prota G: Melanins and Melanogenesis. San Diego: Academic Press; 1992.
24. 2α and PhXA41, a prostaglandin analogue, on the corneal and intraretinal D.C. electroretinogram (ERG) of the albino rabbit eye. Invest Ophthalmol Vis Sci 1994, 35:A3661.
25. Basu S, Sjöquist B, Stjernschantz J, Resul B: Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leuko Essent Fatty Acids 1994, 50:161-168.
26. Sjöquist B, Johansson A: The ocular pharmakokinetics of latanoprost, a new antiglaucoma drug, studied by autoradiography. Invest Ophthalmol Vis Sci 1995, 36:A3809.
27. Aim A, Villumsen J: PhXA34, a new potent ocular hypotensive drug. Arch Ophthalmol 1991, 109:1564-1568.
28. 2α analogue: effect on intraocular pressure in patients with ocular hypertension. Br J Ophthalmol 1992, 76:214-217.
29. Camras CB, Schumer RA, Marsk A, Lustgarten JS, Serle JB, Stjernschantz J, Bito LZ, Podos SM: Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension. Arch Ophthalmol 1992, 110:1733-1738.
30. Aim A, Villumsen J, Törnquist P, Mandahl A, Airaksinen J, Tuulonen A, Marsk A, Resul B, Stjernschantz J: Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure. Ophthalmology 1993, 9:1312-1317.
31. Hotehama Y, Mishima HK, Kitazawa Y, Masuda K: Ocular hypotensive effect of PhXA41 in patients with ocular hypertension or primary openangle glaucoma. Jpn J Ophthalmol 1993, 37:270-274.
32. Nagasubramanian S, Sheth GP, Hitchings RA, Stjernschantz J: Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Ophthalmology 1993, 9:1305-1311.
33. Alm A, Widengárd I, Kjellgren D, Söderström M, Friström B, Heijl A, Stjern• schantz J: Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995, 1:12-16. This article describes a dose-regimen study performed with 0.006% latanoprost in patients undergoing timolol treatment with IOPs before latanoprost of about 25 mm Hg. Once-daily administration of latanoprost was superior to twice daily.
34. 2α analogue (PhXA41): an in-hospital, placebo-controlled study. Arch Ophthalmol 1993, 111:657-661.
35. Kjellgren D, Douglas G, Mikelberg FS, Drance SM, Aim A: The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmol Scand 1995, 73:233-236.
36. Rulo AH, Greve EL, Hoyng PFJ: The ocular hypotensive effect of latanoprost in normal pressure glaucoma patients. Invest Ophthalmol Vis Sci 1995, 36:A3421.
37. Racz P, Ruzsonyi MR, Nagy ZT, Gagyi ZZZ, Bito LZ: Around-the-clock intraocular pressure reduction with once-daily application latanoprost, by itself or in combination with timolol. Arch Ophthalmol 1996, 114:268-273.
38. 2α analogue, and timolol in patients with elevated intraocular pressure. Br J Ophthalmol 1994, 78:899-902.
39. Friström B, Nilsson SEG: Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. Arch Ophthalmol 1993, 111:662-665.
40. Aim A, Stjernschantz J, the Scandinavian Latanoprost Study Group: Ef•• fects on intraocular pressure and side effects of 0.005% latanoprost once daily, evening or morning: a comparison with timolol. Ophthalmology 1995, 102:1743-1752. This article describes a randomized double-masked multicenter trial including a total of 267 patients with open-angle glaucoma or ocular hypertension treated with either 0.005% latanoprost once daily or 0.5% timolol twice daily. Diurnal IOPs were obtained at baseline, 3 months, and 6 months of treatment. Morning versus evening administration was also studied in the latanoprost patients. It is concluded that latanoprost is at least as effective as timolol. Administration of latanoprost in the evening resulted in better diurnal IOP reduction than with timolol. Side effects are discussed in detail.
41. Camras CB, the USA Latanoprost Study Group: Comparison of la•• tanoprost and timolol in patients with ocular hypertension and glaucoma-six-month, masked U.S.A. multicenter trial. Ophthalmology 1995, 103:138-147. This article describes a randomized double-masked multicenter trial, including a total of 268 patients with open-angle glaucoma or ocular hypertension treated with either 0.005% latanoprost once daily or 0.5% timolol twice daily. Diurnal IOPs were obtained at baseline and 6 months of treatment. It is concluded that latanoprost was more effective than timolol. Side effects are discussed in detail.
42. Watson P, Stjernschantz J, the Latanoprost Study Group in United King•• dom: A six month randomized, double-masked study comparing latanoprost to timolol in open angle glaucoma and ocular hypertension. Ophthalmology 1995, 103:126-137. This article describes a randomized double-masked multicenter trial including a total of 294 patients with open-angle glaucoma or ocular hypertension treated with either 0.005% latanoprost once daily or 0.5% timolol twice daily. Diurnal IOPs were obtained at baseline and 6 months of treatment. It is concluded that latanoprost was at least as effective as timolol. Side effects are discussed in detail.
43. Camras CB, Aim A, Watson P: Glaucoma treatment for 1 year with latanoprost, a prostaglandin analog, in the USA, Scandinavia and UK. American Academy of Ophthalmology, Annual Meeting: Atlanta 1995:89.
44. 2α-isopropyl ester eye drops; effects in normal human eyes. Br J Ophthalmol 1989, 73:419-426.